Interview: Kainos Aims To Open New Era With Novel Parkinson’s Drug

 
• By Jung Won Shin

Kainos Medicine’s senior vice president sat down with Scrip to talk about the progress and ambitions for its first-in-class, potentially disease modifying Parkinson's disease drug candidate. If the drug candidate successfully goes through a Phase IIa in the US, it is set to draw robust interest from multinational pharmas which are already active in the area that lacks fundamental treatments.

Kainos Medicine IND approval ceremony
Kainos Medicine's IND Approval Ceremony for KM-819

Kainos Medicine Inc. is a South Korean bioventure that has come under the spotlight recently for the progress it has made with a first-in-class, potentially disease-modifying drug candidate for Parkinson's disease (PD).

So far there seems to be smooth sailing in a Phase I clinical study in South Korea with the molecule, KM-819, and the company is now gearing up protocols for a proof-of-concept Phase IIa trial in the US, a crucial stage for Kainos as success here could draw

More from South Korea

More from Focus On Asia